PMID- 17932424
OWN - NLM
STAT- MEDLINE
DCOM- 20080325
LR  - 20181201
IS  - 1549-4918 (Electronic)
IS  - 1066-5099 (Linking)
VI  - 26
IP  - 1
DP  - 2008 Jan
TI  - Mesenchymal stem cells cooperate with bone marrow cells in therapy of diabetes.
PG  - 244-53
AB  - Several recent studies have suggested that the adult bone marrow harbors cells 
      that can influence beta-cell regeneration in diabetic animals. Other reports, 
      however, have contradicted these findings. To address this issue, we used an 
      animal model of type 1 diabetes in which the disease was induced with 
      streptozotocin in mice. Freshly prepared sex-mismatched bone marrow cells (BMCs) 
      and syngeneic or allogeneic mesenchymal stem cells (MSCs) were concomitantly 
      administrated into sublethally irradiated diabetic mice. Blood glucose and serum 
      insulin concentrations rapidly returned to normal levels, accompanied by 
      efficient tissue regeneration after a single injection of a mixture of 10(6) BMCs 
      per 10(5) MSCs. Neither BMC nor MSC transplantation was effective alone. 
      Successful treatment of diabetic animals was not due to the reconstitution of the 
      damaged islet cells from the transplant, since no donor-derived beta-cells were 
      found in the recovered animals, indicating a graft-initiated endogenous repair 
      process. Moreover, MSC injection caused the disappearance of beta-cell-specific T 
      lymphocytes from diabetic pancreas. Therefore, we suggest that two aspects of 
      this successful treatment regimen operate in parallel and synergistically in our 
      model. First, BMCs and MSCs induce the regeneration of recipient-derived 
      pancreatic insulin-secreting cells. Second, MSCs inhibit T-cell-mediated immune 
      responses against newly formed beta-cells, which, in turn, are able to survive in 
      this altered immunological milieu. Thus, the application of this therapy in human 
      patients suffering from diabetes and/or other tissue destructive autoimmune 
      diseases may be feasible.
FAU - Urban, Veronika S
AU  - Urban VS
AD  - Stem Cell Biology, National Medical Center, Budapest, Hungary.
FAU - Kiss, Judit
AU  - Kiss J
FAU - Kovacs, Janos
AU  - Kovacs J
FAU - Gocza, Elen
AU  - Gocza E
FAU - Vas, Virag
AU  - Vas V
FAU - Monostori, Eva
AU  - Monostori E
FAU - Uher, Ferenc
AU  - Uher F
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20071011
PL  - England
TA  - Stem Cells
JT  - Stem cells (Dayton, Ohio)
JID - 9304532
SB  - IM
MH  - Animals
MH  - Bone Marrow Cells/cytology
MH  - Bone Marrow Transplantation/immunology/*methods
MH  - Diabetes Mellitus, Experimental/*therapy
MH  - Female
MH  - Immunohistochemistry
MH  - In Situ Hybridization
MH  - Lymphocyte Activation/immunology
MH  - Mesenchymal Stem Cell Transplantation/*methods
MH  - Mesenchymal Stem Cells/cytology
MH  - Mice
MH  - T-Lymphocytes/immunology
EDAT- 2007/10/13 09:00
MHDA- 2008/03/26 09:00
CRDT- 2007/10/13 09:00
PHST- 2007/10/13 09:00 [pubmed]
PHST- 2008/03/26 09:00 [medline]
PHST- 2007/10/13 09:00 [entrez]
AID - 2007-0267 [pii]
AID - 10.1634/stemcells.2007-0267 [doi]
PST - ppublish
SO  - Stem Cells. 2008 Jan;26(1):244-53. doi: 10.1634/stemcells.2007-0267. Epub 2007 
      Oct 11.